Kailera Therapeutics, Inc. (KLRA)Healthcare | Biotechnology | Waltham, United States | NasdaqGS
16.21 USD
-2.32
(-12.520%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 16.43 +0.22 (1.357%) ⇧ (Aug. 28, 2026, 7:52 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:12 a.m. EDT
The immediate outlook is clouded by a weak statistical forecast predicting a nearly 4% decline over the next month, compounded by a short ratio of 10.88 that suggests heavy short interest and potential volatility. While the company boasts a fortress balance sheet with a massive $916M cash pile against negligible debt, the lack of any dividend income and negative earnings per share prevent any income-based appeal. The long-term picture remains neutral rather than bullish because the price history is entirely absent; the stock is a newly listed IPO with no multi-year track record to validate the market's initial enthusiasm. Although analysts offer a strong buy recommendation with a target significantly higher than the current price, the absence of historical performance data and the current downward price bias mean there is no clear directional edge for investors to exploit right now. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.088204 |
| MSTL | 0.146020 |
| AutoETS | 0.152685 |
| AutoARIMA | 0.153795 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 1.31 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.172 |
| Excess Kurtosis | -1.04 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.913 |
| Market Cap | 2,101,523,968 |
| Forward P/E | -3.77 |
| Website | https://www.kailera.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.37653846 |
| Address1 | 180 Third Avenue |
| Address2 | 4th Floor |
| All Time High | 28.23 |
| All Time Low | 16.19 |
| Ask | 16.93 |
| Ask Size | 1 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 863,210 |
| Average Daily Volume3 Month | 740,722 |
| Average Volume | 740,722 |
| Average Volume10Days | 863,210 |
| Bid | 16.89 |
| Bid Size | 1 |
| Book Value | 8.629 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 16.21 |
| Current Ratio | 11.108 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 18.26 |
| Day Low | 16.19 |
| Debt To Equity | 0.913 |
| Display Name | Kailera Therapeutics |
| Earnings Timestamp | 1,786,564,800 |
| Earnings Timestamp End | 1,793,304,000 |
| Earnings Timestamp Start | 1,793,304,000 |
| Ebitda | -312,878,016 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.819 |
| Enterprise Value | 1,194,999,040 |
| Eps Current Year | -4.38089 |
| Eps Forward | -4.29631 |
| Eps Trailing Twelve Months | -1.97 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 19.0438 |
| Fifty Day Average Change | -2.8338013 |
| Fifty Day Average Change Percent | -0.1488044 |
| Fifty Two Week Change Percent | -37.653847 |
| Fifty Two Week High | 28.23 |
| Fifty Two Week High Change | -12.02 |
| Fifty Two Week High Change Percent | -0.4257882 |
| Fifty Two Week Low | 16.19 |
| Fifty Two Week Low Change | 0.01999855 |
| Fifty Two Week Low Change Percent | 0.0012352408 |
| Fifty Two Week Range | 16.19 - 28.23 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,776,432,600,000 |
| Float Shares | 58,478,373 |
| Forward Eps | -4.29631 |
| Forward P E | -3.773005 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 145 |
| Fullday Change | -2.32 |
| Fullday Change Percent | -12.5202 |
| Fullday Price | 16.43 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0888 |
| Held Percent Institutions | 0.89615 |
| Implied Shares Outstanding | 129,643,676 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-04-17 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts. |
| Long Name | Kailera Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 2,101,523,968 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1899116257 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -292,196,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,403,593,753 |
| Number Of Analyst Opinions | 5 |
| Open | 18.26 |
| Operating Cashflow | -221,615,008 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 781 317 0290 |
| Post Market Change | 0.22000122 |
| Post Market Change Percent | 1.3571945 |
| Post Market Price | 16.43 |
| Post Market Time | 1,787,961,128 |
| Previous Close | 18.53 |
| Price Eps Current Year | -3.7001612 |
| Price Hint | 2 |
| Price To Book | 1.878549 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.032 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.16667 |
| Region | US |
| Regular Market Change | -2.32 |
| Regular Market Change Percent | -12.5202 |
| Regular Market Day High | 18.26 |
| Regular Market Day Low | 16.19 |
| Regular Market Day Range | 16.19 - 18.26 |
| Regular Market Open | 18.26 |
| Regular Market Previous Close | 18.53 |
| Regular Market Price | 16.21 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 531,875 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 129,643,676 |
| Shares Percent Shares Out | 0.0468 |
| Shares Short | 6,065,081 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 6,413,693 |
| Short Name | Kailera Therapeutics, Inc. |
| Short Percent Of Float | 0.0468 |
| Short Ratio | 14.94 |
| Source Interval | 15 |
| State | MA |
| Symbol | KLRA |
| Target High Price | 57.0 |
| Target Low Price | 30.0 |
| Target Mean Price | 42.4 |
| Target Median Price | 41.0 |
| Total Cash | 916,740,992 |
| Total Cash Per Share | 7.071 |
| Total Debt | 10,216,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.97 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 20.458065 |
| Two Hundred Day Average Change | -4.248066 |
| Two Hundred Day Average Change Percent | -0.20764749 |
| Type Disp | Equity |
| Volume | 531,875 |
| Website | https://www.kailera.com |
| Zip | 2,451 |